Cat. #156470
CCRF-CEM-R5 Cell line
Cat. #: 156470
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-5 days
Organism: Human
Tissue: Bone Marrow
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Aintzane Asumendi ; Aintzane Apraiz ; Dolores Boyano
Institute: University of the Basque Country (EHU)
Tool Details
*FOR RESEARCH USE ONLY
- Name: CCRF-CEM-R5 Cell line
- Tool sub type: Continuous
- Parental cell: CCRF-CEM
- Organism: Human
- Tissue: Bone Marrow
- Disease: Cancer
- Growth properties: Cell grow in suspension
- Model: Tumour line
- Conditional: No
- Description: 4-HPR is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, including leukemia cells.
- Production details: CCRF-CEM-R5 cell line, resistant to up to 5 mM of 4-HPR, was obtained by gradual selection. Parental CCRF-CEM cells were continuously exposed to increasing 4-HPR concentrations, starting from 0.5 mM.
- Recommended controls: Control cells are CCRF-CEM parental cells that are sensitive to higher than 1mM 4HPR
Target Details
- Target: Relevant disease (Acute Lymphoblastic Leukemia/ALL); Drug (synthetic retinoid 4-HPR: fenretinide or N-(4-hydroxyphenyl)retinamide)
Handling
- Format: Frozen
- Growth medium: Cells should be grown in RPMI 1640 with 2mM L-glutamine supplemented with 10% heat inactivated FBS. Keep at 37?°C in a humidified incubator containing 5% CO2. In order to preserve their resistant intermitent exposures to 5mM 4-HPR is recomended. 4-HPR removal from R5 cell culture for up to 8 passages or 3 weeks has not shown any decrease on drug resistance although it does affect endogenous sphingolipid profile (specified in the reference paper).
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Apraiz et al. 2011. BMC Cancer. 11:477. PMID: 22061047.
